

Sagepath Labs Pvt. Ltd. Registered Office:- # Plot No. 564 , 1st floor , Buddhanagar , Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg .No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com Website:- www.sagepathlabs.com

-	REPUR		
Name	: Mrs. SRAVANTHI	Sample ID	: 24854382
Age/Gender	: 42 Years/Female	Reg. No	: 0312310020033
Referred by	: Dr. TEJASHWI	SPP Code	: SPL-CV-172
Referring Customer	· · · V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
Primary Sample	:	Received On	: 02-Oct-2023 12:56 PM
Sample Tested In	: Capillary Tube	Reported On	: 02-Oct-2023 09:10 PM
Client Address	: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report

HAEMATOLOGY				
Test Name	Results	Units	Ref. Range	Method
Bleeding Time & Clotting Time				
Bleeding Time (BT)	03 min 30	sec Minutes	2 - 5	Capillary Method
Clotting Time (CT)	05 min 40	sec Minutes	3 - 7	Capillary Method

\*\*\* End Of Report \*\*\*



Swarnabala.M DR.SWARNA BALA MD PATHOLOGY

\*TESTS CONDUCTED @ CENTRAL LAB, HYDERABAD

Note : This report is subject to the terms and conditions overleaf. Partial Reproduction of this report is not Permitted



Registered Office:- # Plot No. 564 , 1st floor , Buddhanagar , Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg .No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com

-	REPOR	Website:- www.sagep	athlabs.com
Name	: Mrs. SRAVANTHI	Sample ID	: 24854405
Age/Gender	: 42 Years/Female	Reg. No	: 0312310020033
Referred by	: Dr. TEJASHWI	SPP Code	: SPL-CV-172
Referring Customer	: V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
Primary Sample	: Whole Blood	Received On	: 02-Oct-2023 12:56 PM
Sample Tested In	: Citrated Plasma	Reported On	: 02-Oct-2023 09:13 PM
Client Address	: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report

HAEMATOLOGY				
Test Name	Results	Units	Ref. Range	Method
<u>PROTHROMBIN TIME (P TIME)</u>				
PT-Patient Value	17.5	Secs	10-15	Photo Optical Clot Detection
PT-Mean Control Value	13.00	Seconds		
PT Ratio	1.35			
PT INR	1.50		0.9-1.2	

**Interpretation :** 

Prothrombin time measures the extrinsic coagulation pathway which consists of activated Factor VII (VIIa), Tissue factor and Proteins of the common pathway (Factors X, V, II & Fibrinogen). This assay is used to control long term oral anticoagulant therapy, evaluation of liver function & to evaluate coagulation disorders specially factors involved in the extrinsic pathway like Factors V, VII, X, Prothrombin & Fibrinogen.

Note

1. INR is the parameter of choice in monitoring adequacy of oral anticoagulant therapy. Appropriate therapeutic range varies with the disease and treatment intensity

2. Prolonged INR suggests potential bleeding disorder / bleeding complications

3. Results should be clinically correlated

4. Test conducted on Citrated plasma



Swarnabala.M DR.SWARNA BALA **MD PATHOLOGY** 

\*TESTS CONDUCTED @ CENTRAL LAB, HYDERABAD

Note : This report is subject to the terms and conditions overleaf. Partial Reproduction of this report is not Permitted



Registered Office:- # Plot No. 564, 1st floor, Buddhanagar, Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg.No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com Website:- www.sagepathlabs.com

REPORT -

KEPU		
: Mrs. SRAVANTHI	Sample ID	: 24854404
: 42 Years/Female	Reg. No	: 0312310020033
: Dr. TEJASHWI	SPP Code	: SPL-CV-172
: V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
: Whole Blood	Received On	: 02-Oct-2023 12:56 PM
: Whole Blood EDTA	Reported On	: 02-Oct-2023 04:37 PM
: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report
	: Mrs. SRAVANTHI : 42 Years/Female : Dr. TEJASHWI : V CARE MEDICAL DIAGNOSTICS : Whole Blood : Whole Blood EDTA	: Mrs. SRAVANTHI Sample ID : 42 Years/Female Reg. No : Dr. TEJASHWI SPP Code : V CARE MEDICAL DIAGNOSTICS Collected On : Whole Blood EDTA Received On

HAEMATOLOGY SURGICAL PROFILE-II Test Name Results Units Ref. Range Method Blood Grouping (A B O) 0 **Tube Agglutination Rh** Typing Positive **Tube Agglutination** Result rechecked and verified for abnormal cases \*\*\* End Of Report \*\*\* Laboratory is NABL Accredited









Swarnabala - M DR.SWARNA BALA MD PATHOLOGY



Sagepath Labs Pvt. Ltd. Registered Office:- # Plot No. 564 , 1st floor , Buddhanagar , Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg .No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com Website:- www.sagepathlabs.com

	REPORT -	website. www.sagepath	1003.0011
Name	: Mrs. SRAVANTHI	Sample ID	: 24854404
Age/Gender	: 42 Years/Female	Reg. No	: 0312310020033
Referred by	: Dr. TEJASHWI	SPP Code	: SPL-CV-172
Referring Customer	: V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
Primary Sample	: Whole Blood	Received On	: 02-Oct-2023 12:56 PM
Sample Tested In	: Whole Blood EDTA	Reported On	: 02-Oct-2023 04:55 PM
Client Address	: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report

OSE INFOSYSTEMS PVT. LTD.

HAEMATOLOGY					
	SURGICAL PROFILE-II				
Test Name	Results	Units	Ref. Range	Method	
Complete Blood Picture(CBP)					
Haemoglobin (Hb)	8.0	g/dL	12-15	Cynmeth Method	
Haematocrit (HCT)	26.5	%	40-50	Calculated	
RBC Count	4.37	10^12/L	4.5-5.5	Cell Impedence	
MCV	61	fl	81-101	Calculated	
MCH	18.3	pg	27-32	Calculated	
МСНС	30.1	g/dL	32.5-34.5	Calculated	
RDW-CV	17.8	%	11.6-14.0	Calculated	
Platelet Count (PLT)	433	10^9/L	150-410	Cell Impedance	
Total WBC Count	5.9	10^9/L	4.0-10.0	Impedance	
Differential Leucocyte Count (DC)					
Neutrophils	61	%	40-70	Cell Impedence	
Lymphocytes	32	%	20-40	Cell Impedence	
Monocytes	04	%	2-10	Microscopy	
Eosinophils	03	%	1-6	Microscopy	
Basophils	0	%	1-2	Microscopy	
Absolute Neutrophils Count	3.6	10^9/L	2.0-7.0	Impedence	
Absolute Lymphocyte Count	1.89	10^9/L	1.0-3.0	Impedence	
Absolute Monocyte Count	0.24	10^9/L	0.2-1.0	Calculated	
Absolute Eosinophils Count	0.18	10^9/L	0.02-0.5	Calculated	
Absolute Basophil ICount	0.00	10^9/L	0.0-0.3	Calculated	
Morphology	Anisocytosis Thrombocyt		ic hypochromic anemia and	PAPs Staining	







Swarnabala.M DR.SWARNA BALA MD PATHOLOGY

 $\overline{MC}$  3633 terms and conditions overleaf. Partial Reproduction of this report is not Permitted

\*TESTS CONDUCTED @ CENTRAL LAB, HYDERABAD



**ilac-MRA** 

hilalah

Sagepath Labs Pvt. Ltd. Registered Office:- # Plot No. 564 , 1st floor , Buddhanagar , Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg .No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com Website:-www.sagepathlabs.com

REPORT

Seferred by       : Dr. TEJASHWI       SPP Code       : SPL-CV-172         Seferring Customer       : V CARE MEDICAL DIAGNOSTICS       Collected On       : 02-Oct-2023 12:3         imary Sample       : Whole Blood       Received On       : 02-Oct-2023 12:3         ample Tested In       : Plasma-NaF(R), Serum       Reported On       : 02-Oct-2023 07:2         ient Address       : Kimtee colony ,Gokul Nagar,Tarnaka       Report Status       : Final Report         CLINICAL BIOCHEMISTRY         SURGICAL PROFILE-II         Cest Name       Results       Units       Ref. Range       Method         Glucose Random (RBS)       89       mg/dL       70-140       Hexokinase (Hk         Interpretation of Plasma Glucose based on ADA guidelines 2018
eferred by       :       Dr. TEJASHWI       SPP Code       :       SPL-CV-172         eferring Customer       :       V CARE MEDICAL DIAGNOSTICS       Collected On       :       02-Oct-2023 12:3         rimary Sample       :       Whole Blood       Received On       :       02-Oct-2023 12:5         ample Tested In       :       Plasma-NaF(R), Serum       Reported On       :       02-Oct-2023 07:2         lient Address       :       Kimtee colony ,Gokul Nagar,Tarnaka       Report Status       :       Final Report         CLINICAL BIOCHEMISTRY         SURGICAL PROFILE-II         Test Name       Results       Units       Ref. Range       Method         Glucose Random (RBS)       89       mg/dL       70-140       Hexokinase (Hk         Interpretation of Plasma Glucose based on ADA guidelines 2018       Edignosis       FastingPlasma Glucose(mg/dL)       HbA1c(%)       RBS(mg/dL)         Prediabetes       100-125       140-199       5.7-6.4       NA       >=200(with symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         Reference: Diabetes care 2018:41(suppl.1):S13-S27         The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and poly
eferring Customer : V CARE MEDICAL DIAGNOSTICS       Collected On : 02-Oct-2023 12:3         rimary Sample : Whole Blood       Received On : 02-Oct-2023 12:5         ample Tested In : Plasma-NaF(R), Serum       Reported On : 02-Oct-2023 07:2         lient Address : Kimtee colony ,Gokul Nagar, Tarnaka       Report don : 02-Oct-2023 07:2         lient Address : Kimtee colony ,Gokul Nagar, Tarnaka       Report Status : Final Report         CLINICAL BIOCHEMISTRY         SURGICAL PROFILE-II         Test Name       Results       Units       Ref. Range       Method         Glucose Random (RBS)       89       mg/dL       70-140       Hexokinase (Hk         Interpretation of Plasma Glucose based on ADA guidelines 2018         Diagnosis       FastingPlasma Glucose(mg/dL)       HbA1c(%)       RBS(mg/dL)         Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       > = 126       > = 200       > = 6.5       symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
timary Sample       : Whole Blood       Received On       : 02-Oct-2023 12:5         ample Tested In       : Plasma-NaF(R), Serum       Reported On       : 02-Oct-2023 07:2         lient Address       : Kimtee colony ,Gokul Nagar,Tarnaka       Report Status       : Final Report         CLINICAL BIOCHEMISTRY         SURGICAL PROFILE-II         Test Name       Results       Units       Ref. Range       Method         Glucose Random (RBS)       89       mg/dL       70-140       Hexokinase (Hk         Interpretation of Plasma Glucose based on ADA guidelines 2018         Diagnosis       FastingPlasma Glucose(mg/dL)       HbA1c(%)       RBS(mg/dL)         Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       > = 126       > = 200       > = 6.5       symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
ample Tested In       : Plasma-NaF(R), Serum       Reported On       : 02-Oct-2023 07:2         lient Address       : Kimtee colony ,Gokul Nagar,Tarnaka       Report Status       : Final Report         CLINICAL BIOCHEMISTRY         SURGICAL PROFILE-II         Test Name       Results       Units       Ref. Range       Method         Glucose Random (RBS)       89       mg/dL       70-140       Hexokinase (HK         Interpretation of Plasma Glucose based on ADA guidelines 2018         Diagnosis       FastingPlasma Glucose(mg/dL)       PhrsPlasma Glucose(mg/dL)       HbA1c(%)       RBS(mg/dL)         Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       > = 126       > = 200       > = 6.5       symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
ample Tested In       : Plasma-NaF(R), Serum       Reported On       : 02-Oct-2023 07:2         lient Address       : Kimtee colony ,Gokul Nagar,Tarnaka       Report Status       : Final Report         CLINICAL BIOCHEMISTRY         SURGICAL PROFILE-II         Test Name       Results       Units       Ref. Range       Method         Glucose Random (RBS)       89       mg/dL       70-140       Hexokinase (Hk         Interpretation of Plasma Glucose based on ADA guidelines 2018         Diagnosis       FastingPlasma Glucose(mg/dL)       PhrsPlasma Glucose(mg/dL)       HbA1c(%)       RBS(mg/dL)         Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       > = 126       > = 200       > = 6.5       symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
Itent Address       Kimtee colony ,Gokul Nagar,Tarnaka       Report Status       Final Report         CLINICAL BIOCHEMISTRY         SURGICAL PROFILE-II         Test Name       Results       Units       Ref. Range       Method         Glucose Random (RBS)       89       mg/dL       70-140       Hexokinase (HK         Interpretation of Plasma Glucose based on ADA guidelines 2018       Entroperation of Plasma Glucose based on ADA guidelines 2018       HbA1c(%)       RBS(mg/dL)       Prediabetes       100-125       140-199       5.7-6.4       NA         Diagnosis       FastingPlasma Glucose (mg/dL)       210       > = 6.5       >=200(with symptoms)       >= 0.5       >=200(with
CLINICAL BIOCHEMISTRY         SURGICAL PROFILE-II         Test Name       Results       Units       Ref. Range       Method         Glucose Random (RBS)       89       mg/dL       70-140       Hexokinase (HK         Interpretation of Plasma Glucose based on ADA guidelines 2018       Prediabetes       100-125       140-199       5.7-6.4       NA         Diagnosis       FastingPlasma Glucose(mg/dL)       Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       > = 126       > = 200       > = 6.5       >=200(with symptoms)       >= 6.5       >=200(with symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
SURGICAL PROFILE-II         Test Name       Results       Units       Ref. Range       Method         Glucose Random (RBS)       89       mg/dL       70-140       Hexokinase (HK         Interpretation of Plasma Glucose based on ADA guidelines 2018       Interpretation of Plasma Glucose (mg/dL)       Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       100-125       140-199       5.7-6.4       NA       Interpretation symptoms)         Reference:       Diabetes $2012$ >= 200       >= 6.5       symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
Test Name       Results       Units       Ref. Range       Method         Glucose Random (RBS)       89       mg/dL       70-140       Hexokinase (Hk         Interpretation of Plasma Glucose based on ADA guidelines 2018       Interpretations       FastingPlasma Glucose(mg/dL)       HbA1c(%)       RBS(mg/dL)         Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       > = 126       > = 200       > = 6.5       >=200(with symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
Interpretation of Plasma Glucose based on ADA guidelines 2018         Diagnosis       FastingPlasma Glucose(mg/dL)       2hrsPlasma Glucose(mg/dL)       HbA1c(%)       RBS(mg/dL)         Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       > = 126       > = 200       > = 6.5       symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
Interpretation of Plasma Glucose based on ADA guidelines 2018         Diagnosis       FastingPlasma Glucose(mg/dL)       2hrsPlasma Glucose(mg/dL)       HbA1c(%)       RBS(mg/dL)         Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       > = 126       > = 200       > = 6.5       >=200(with symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
Diagnosis       FastingPlasma Glucose(mg/dL)       2hrsPlasma Glucose(mg/dL)       HbA1c(%)       RBS(mg/dL)         Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       > = 126       > = 200       > = 6.5       >=200(with symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
Diagnosis       Glucose(mg/dL)       Glucose(mg/dL)       HDA TC(76)       RES(filg/dL)         Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       > = 126       > = 200       > = 6.5       symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
Prediabetes       100-125       140-199       5.7-6.4       NA         Diabetes       > = 126       > = 200       > = 6.5       > = 200(with symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         • The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
Diabetes       > = 126       > = 200       > = 6.5       symptoms)         Reference: Diabetes care 2018:41(suppl.1):S13-S27         The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
• The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
• The random blood glucose if it is above 200 mg/dL and the patient has increased thirst, polyuria, and polyphagia, suggests diabetes mellitus.
Jrea 21.6 mg/dL 12.8-42.8 Glutamate
<ul> <li>Catabolism of proteins and amino acids results in the formation of urea, which is predominantly cleared from the body by the kidneys.</li> <li>Increased urea with normal creatinine concentrations indicates a pre-renal increase in urea which may be due to a high protein diet, increased protein catabolism, reabsorption of the formation o</li></ul>
<ul> <li>Proteins after GI haemorrhage, glucocorticoid treatment, dehydration or decreased perfusion of the kidneys.</li> <li>An increase in both urea and creatinine concentrations may indicate an obstructive post-renal condition such as malignancy, nephrolithiasis or prostatism.</li> <li>A low urea and increased creatinine may indicate acute tubular necrosis, low protein intake, starvation or severe liver disease.</li> </ul>
<ul> <li>An increase in both urea and creatinine concentrations may indicate an obstructive post-renal condition such as malignancy, nephrolithiasis or prostatism.</li> <li>A low urea and increased creatinine may indicate acute tubular necrosis, low protein intake, starvation or severe liver disease.</li> </ul> Creatinine -Serum 0.85 mg/dL 0.60-1.10 Sarcosine oxidation
<ul> <li>An increase in both urea and creatinine concentrations may indicate an obstructive post-renal condition such as malignancy, nephrolithiasis or prostatism.</li> <li>A low urea and increased creatinine may indicate acute tubular necrosis, low protein intake, starvation or severe liver disease.</li> </ul>
<ul> <li>An increase in both urea and creatinine concentrations may indicate an obstructive post-renal condition such as malignancy, nephrolithiasis or prostatism.</li> <li>A low urea and increased creatinine may indicate acute tubular necrosis, low protein intake, starvation or severe liver disease.</li> </ul> Creatinine -Serum <ul> <li>0.85</li> <li>mg/dL</li> <li>0.60-1.10</li> <li>Sarcosine oxida</li> </ul> Interpretation: <ul> <li>This test is done to see how well your kidneys are working. Creatinine is a chemical waste product of creatine. Creatine is a chemical made by the body and is used to supply-muscles.</li> <li>A higher than normal level may be due to:</li> <li>Real diseases and insufficiency with decreased glomerular filtration, urinary tract obstruction, reduced renal blood flow including congestive heart failure, shock, and dehydratior can cause elevated serum creatinine.</li> <li>A lower than normal level may be due to:</li> <li>Small stature, debilitation, decreased muscle mass; some complex cases of severe hepatic disease can cause low serum creatinine levels. In advanced liver disease, low creating for decreased hepatic production of creatinine and inadequate dietary protein as well as reduced musle mass.</li> </ul>
<ul> <li>An increase in both urea and creatinine concentrations may indicate an obstructive post-renal condition such as malignancy, nephrolithiasis or prostatism.</li> <li>A low urea and increased creatinine may indicate acute tubular necrosis, low protein intake, starvation or severe liver disease.</li> </ul> Creatinine -Serum <ul> <li>0.85</li> <li>mg/dL</li> <li>0.60-1.10</li> <li>Sarcosine oxida</li> </ul> Interpretation: <ul> <li>This test is done to see how well your kidneys are working. Creatinine is a chemical waste product of creatine. Creatine is a chemical made by the body and is used to supply-muscles.</li> <li>A higher than normal level may be due to:</li> <li>Renal diseases and insufficiency with decreased glomerular filtration, urinary tract obstruction, reduced renal blood flow including congestive heart failure, shock, and dehydratior can cause elevated serum creatinine. <ul> <li>A lower than normal level may be due to:</li> <li>Small stature, debilitation, decreased muscle mass; some complex cases of severe hepatic disease can cause low serum creatinine levels. In advanced liver disease, low creation decreased hepatic production of creatinine and inadequate dietary protein as well as reduced musle mass.</li> </ul></li></ul>

 $\overline{MC}$  3633 terms and conditions overleaf. Partial Reproduction of this report is not Permitted

DR.VAISHNAVI MD BIOCHEMISTRY



Registered Office:- # Plot No. 564 , 1st floor , Buddhanagar , Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg .No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com

-	REPOR	RT Website:- www.sagepa	athlabs.com
Name	: Mrs. SRAVANTHI	Sample ID	: 24854404
Age/Gender	: 42 Years/Female	Reg. No	: 0312310020033
Referred by	: Dr. TEJASHWI	SPP Code	: SPL-CV-172
Referring Customer	: V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
Primary Sample	: Whole Blood	Received On	: 02-Oct-2023 12:56 PM
Sample Tested In	: Whole Blood EDTA	Reported On	: 02-Oct-2023 07:13 PM
Client Address	: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report

CLINICAL BIOCHEMISTRY				
Test Name	Results	Units	Ref. Range	Method
Glycated Hemoglobin (HbA1c)	5.6	%	Non Diabetic:< 5.7 Pre diabetic: 5.7-6.4 Diabetic:>= 6.5	HPLC
Mean Plasma Glucose	114.02	mg/dL		Calculated

**Interpretation:** 

• Glycated hemoglobins (GHb), also called glycohemoglobins, are substances formed when glucose binds to hemoglobin, and occur in amounts proportional to the concentration of serum glucose. Since red blood cells survive an average of 120 days, the measurement of GHb provides an index of a person's average blood glucose concentration (glycemia) during the preceding 2-3 months. Normally, only 4% to 6% of hemoglobin is bound to glucose, while elevated glycohemoglobin levels are seen in diabetes and other hyperglycemic states

Mean Plasma Glucose(MPG): This Is Mathematical Calculations Where Glycated Hb Can Be Correlated With Daily Mean Plasma Glucose Level

Laboratory is NABL Accredited

\*\*\* End Of Report \*\*\*











Registered Office:- # Plot No. 564 , 1st floor , Buddhanagar , Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg .No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com Website:- www.sagepathlabs.com

-	REPU		
Name	: Mrs. SRAVANTHI	Sample ID	: 24854403
Age/Gender	: 42 Years/Female	Reg. No	: 0312310020033
Referred by	: Dr. TEJASHWI	SPP Code	: SPL-CV-172
Referring Customer	: V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
Primary Sample	: Whole Blood	Received On	: 02-Oct-2023 12:56 PM
Sample Tested In	: Serum	Reported On	: 02-Oct-2023 07:21 PM
Client Address	: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report

**CLINICAL BIOCHEMISTRY** Test Name Results Units Ref. Range Method **TSH - Thyroid Stimulating Hormone** CLIA 1.76 µIU/mL 0.35-5.5

Pregnancy & Cord Blood	
	TSH (Thyroid Stimulating Hormone (µIU/mL)
First Trimester : 0.24-2.99	
Second Trimester : 0.46-2.95	
Third Trimester : 0.43-2.78	

• TSH is synthesized and secreted by the anterior pituitary in response to a negative feedback mechanism involving concentrations of FT3 (free T3) and FT4 (free T4). Additionally, the hypothalamic tripeptide, thyrotropin-releasing hormone (TRH), directly stimulates TSH production.

TSH interacts with specific cell receptors on the thyroid cell surface and exerts two main actions. The first action is to stimulate cell reproduction and hypertrophy. Secondly, TSH stimulates the thyroid gland to synthesize and secrete T3 and T4

• The ability to quantitate circulating levels of TSH is important in evaluating thyroid function. It is especially useful in the differential diagnosis of primary (thyroid) from secondary (pituitary) and tertiary (hypothalamus) hypothyroidism. In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low

• TRH stimulation differentiates secondary and tertiary hypothyroidism by observing the change in patient TSH levels. Typically, the TSH response to TRH stimulation is absent in cases of secondary hypothyroidism, and normal to exaggerated in tertiary hypothyroidism

• Historically, TRH stimulation has been used to confirm primary hyperthyroidism, indicated by elevated T3 and T4 levels and low or undetectable TSH levels. TSH assays with increased sensitivity and specificity provide a primary diagnostic tool to differentiate hyperthyroid from euthyroid patients.

\*\*\* End Of Report \*\*\*

Laboratory is NABL Accredited

· 2 3-13 2

Cord Blood











Registered Office:- # Plot No. 564, 1st floor, Buddhanagar, Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg.No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com Website:- www.sagepathlabs.com

	REPOR		
Name	: Mrs. SRAVANTHI	Sample ID	: 24854403
Age/Gender	: 42 Years/Female	Reg. No	: 0312310020033
Referred by	: Dr. TEJASHWI	SPP Code	: SPL-CV-172
Referring Customer	: V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
Primary Sample	: Whole Blood	Received On	: 02-Oct-2023 12:56 PM
Sample Tested In	: Serum	Reported On	: 02-Oct-2023 05:31 PM
Client Address	: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report

CLINICAL BIOCHEMISTRY				
Test Name	Results	Units	Ref. Range	Method
Liver Function Test (LFT)				
Bilirubin(Total)	0.3	mg/dL	0.3-1.2	Diazo
Bilirubin (Direct)	0.2	mg/dL	0.0 - 0.2	Diazo
Bilirubin (Indirect)	0.1	mg/dL	0.2-1.0	Calculated
Aspartate Aminotransferase (AST/SGOT)	17	U/L	5-40	IFCC with out (P-5-P)
Alanine Aminotransferase (ALT/SGPT)	10	U/L	0-55	IFCC with out (P-5-P)
Alkaline Phosphatase(ALP)	65	U/L	40-150	Kinetic PNPP-AMP
Gamma Glutamyl Transpeptidase (GGTP)	28	U/L	5-55	IFCC
Protein - Total	7.5	g/dL	6.4-8.2	Biuret
Albumin	3.9	g/dL	3.4-5.0	Bromocresol purple (BCP)
Globulin	3.6	g/dL	2.0-4.2	Calculated
A:G Ratio	1.08	%	0.8-2.0	Calculated

• Alanine Aminotransferase(ALT) is an enzyme found in liver and kidneys cells. ALT helps create energy for liver cells. Damaged liver cells release ALT into the bloodstream, which can elevate ALT levels in the blood.

- Aspartate Aminotransferase (AST) is an enzyme in the liver and muscles that helps metabolizes amino acids. Similarly to ALT, elevated AST levels may be a sign of liver damage or liver disease.
- Alkaline phosphate (ALP) is an enzyme present in the blood. ALP contributes to numerous vital bodily functions, such as supplying nutrients to the liver, promoting bone growth, and metabolizing fat in the intestines.
- Gamma-glutamyl Transpeptidase (GGTP) is an enzyme that occurs primarily in the liver, but it is also present in the kidneys, pancreas, gallbladder, and spleen. Higher than normal concentrations of GGTP in the blood may indicate alcohol-related liver damage. Elevated GGTP levels can also increase the risk of developing certain types of cancer.
- **Bilirubin** is a waste product that forms when the liver breaks down red blood cells. Bilirubin exits the body as bile in stool. High levels of bilirubin can cause jaundice a condition in which the skin and whites of the eyes turn yellow- and may indicate liver damage.
- Albumin is a protein that the liver produces. The liver releases albumin into the bloodstream, where it helps fight infections and transport vitamins, hormones, and enzymes throughout the body. Liver damage can cause abnormally low albumin levels.











Registered Office:- # Plot No. 564, 1st floor, Buddhanagar, Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg.No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com

REPORT Website:- www.sagepathlabs.com

	REPU		
Name	: Mrs. SRAVANTHI	Sample ID	: 23259703
Age/Gender	: 42 Years/Female	Reg. No	: 0312310020033
Referred by	: Dr. TEJASHWI	SPP Code	: SPL-CV-172
Referring Customer	: V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
Primary Sample	:	Received On	: 02-Oct-2023 12:56 PM
Sample Tested In	: Urine	Reported On	: 02-Oct-2023 02:01 PM
Client Address	: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report

CLINICAL PATHOLOGY				
	SURGI	CAL PROFIL	_E-II	
Test Name	Results	Units	Ref. Range	Method
Complete Urine Analysis (CUE)				
Physical Examination				
Colour	Pale Yellow		Straw to light amber	
Appearance	Clear		Clear	
Chemical Examination				
Glucose	Negative		Negative	Strip Reflectance
Protein	Absent		Negative	Strip Reflectance
Bilirubin (Bile)	Negative		Negative	Strip Reflectance
Urobilinogen	Negative		Negative	Ehrlichs reagent
Ketone Bodies	Negative		Negative	Strip Reflectance
Specific Gravity	1.025		1.000 - 1.030	Strip Reflectance
Blood	Negative		Negative	Strip Reflectance
Reaction (pH)	7.0		5.0 - 8.5	Reagent strip Reflectance - Double indicator Principle
Nitrites	Negative		Negative	Strip Reflectance
Leukocyte esterase	Negative		Negative	Reagent Strip Reflectance
Microscopic Examination (Microscopy)				
PUS(WBC) Cells	02-03	/hpf	00-05	Microscopy
R.B.C.	Nil	/hpf	Nil	Microscopic
Epithelial Cells	01-02	/hpf	00-05	Microscopic
Casts	Absent		Absent	Microscopic
Crystals	Absent		Absent	Microscopic
Bacteria	Nil		Nil	
Budding Yeast Cells	Nil		Absent	Microscopy
Others	-			Microscopic

Comments :

Urine analysis is one of the most useful laboratory tests as it identifies a wide range of medical conditions including renal damage, urinary tract infections, diabetes, hypertension and drug toxicity.

\*TESTS CONDUCTED @ CENTRAL LAB, HYDERABAD





Swarnabala - M DR.SWARNA BALA MD PATHOLOGY



Registered Office:- # Plot No. 564, 1st floor, Buddhanagar, Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg.No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com Website:- www.sagepathlabs.com

	REPOR		
Name	: Mrs. SRAVANTHI	Sample ID	: 24854403
Age/Gender	: 42 Years/Female	Reg. No	: 0312310020033
Referred by	: Dr. TEJASHWI	SPP Code	: SPL-CV-172
Referring Custom	er : V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
Primary Sample	: Whole Blood	Received On	: 02-Oct-2023 12:56 PM
Sample Tested In	: Serum	Reported On	: 02-Oct-2023 07:47 PM
Client Address	: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report

IMMUNOLOGY & SEROLOGY						
SURGICAL PROFILE-II						
Test Name	Results	Units	Ref. Range	Method		
VDRL- Syphilis Antibodies Non Reactive Non Reactive Slide Flocculation						

The serological diagnosis of syphilis is classified into two groups: Nontreponemal tests (RPR/VDRL) and Treponemal tests (TPHA/CLIA). Syphilis serology is a treponemal assay for the qualitative determination of antibodies to T. pallidum in human serum or plasma as an aid in the diagnosis of syphilis. Treponemal tests may remain reactive for life, even following adequate therapy thus a positive result suggests infection with Treponema pallidum but does not distinguish between treated and untreated infections. Therefore, the results of a nontreponemal assay, such as rapid plasma reagin, are needed to provide information on a patient's disease state and history of therapy. Nontreponemal tests lack sensitivity in late stage of infection and screening with these tests alone may yield false positive reactions in various acute and chronic conditions in the absence of syphilis (biological false positive reactions).

Result rechecked and verified for abnormal cases

\*\*\* End Of Report \*\*\*


Laboratory is NABL Accredited

# Excellence In Health Care











Registered Office:- # Plot No. 564, 1st floor, Buddhanagar, Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg. No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com Website:- www.sagepathlabs.com

	REPOI	RI	
Name	: Mrs. SRAVANTHI	Sample ID	: 24854403
Age/Gender	: 42 Years/Female	Reg. No	: 0312310020033
Referred by	: Dr. TEJASHWI	SPP Code	: SPL-CV-172
Referring Customer	: V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
Primary Sample	: Whole Blood	Received On	: 02-Oct-2023 12:56 PM
Sample Tested In	: Serum	Reported On	: 02-Oct-2023 07:40 PM
Client Address	: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report

IMMUNOLOGY & SEROLOGY					
SURGICAL PROFILE-II					
Test Name	Results	Units	Ref. Range	Method	
Hepatitis B Surface Antigen (HBsAg)	0.35	S/Co	<1.00 :Negative >1.00 :Positive	ELISA	


Interpretation:

TDOSE INFOSYSTEMS PVT. LTD.

- Negative result implies that antibodies to HBsAg have not been detected in the sample. This means the patient has either not been exposed to HBsAg infection
  or the sample has been tested during the "window phase" i.e. before the development of detectable levels of antibodies. Hence a Non-Reactive result does not
  exclude the possibility of exposure or infection with HBsAg.
- Positive result implies that antibodies to HBsAg have been detected in the sample.

HBV antigens and antibodies in the blood

Hepatitis B Virus (HBV) is a member of the Hepadna virus family causing infections of the liver with extremely variable clinical features. Hepatitis B is transmitted primarily by body fluids especially serum and also spread effectively sexually and from mother to baby. In most individuals HBV hepatitis is self limiting, but 1-2% normal adolescents and adults develop Chronic Hepatitis. Frequency of chronic HBV infection is 5-10% in immunocompromised patients and 80% in neonates. The initial serological marker of acute infection is HBsAg which typically appears 2-3 months after infection and disappears 12-20 weeks after onset of symptoms. Persistence of HBsAg for more than six months indicates development of carrier state or Chronic liver disease.



1. All Reactive results are tested additionally by Specific antibody Neutralization assay . For further confirmation Molecular assays are recommended For diagnostic purposes, results should be used in conjunction with clinical history and other hepatitis markers for Acute or Chronic infection

\*\*\* End Of Report \*\*\*

Laboratory is NABL Accredited



DR. RUTURAJ MANIKLAL KOLHAPURE MD, MICROBIOLOGIST



Registered Office:- # Plot No. 564 , 1st floor , Buddhanagar , Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg .No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com Website:- www.sagepathlabs.com

REPORT	- Website. WWW.sugepu	
: Mrs. SRAVANTHI	Sample ID	: 24854403
: 42 Years/Female	Reg. No	: 0312310020033
: Dr. TEJASHWI	SPP Code	: SPL-CV-172
: V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
: Whole Blood	Received On	: 02-Oct-2023 12:56 PM
: Serum	Reported On	: 02-Oct-2023 07:35 PM
: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report
	: Mrs. SRAVANTHI : 42 Years/Female : Dr. TEJASHWI : V CARE MEDICAL DIAGNOSTICS : Whole Blood : Serum	: Mrs. SRAVANTHISample ID: 42 Years/FemaleReg. No: Dr. TEJASHWISPP Code: V CARE MEDICAL DIAGNOSTICSCollected On: Whole BloodReceived On: SerumReported On


IMMUNOLOGY & SEROLOGY					
SURGICAL PROFILE-II					
Test Name	Results	Units	Ref. Range	Method	
Hepatitis C Virus Antibody       0.23       S/Co       < 1.00 : Negative       ELISA         > 1.00 : Positive       > 1.00 : Positive       > 1.00 : Positive       > 1.00 : Positive					

Interpretation:

- 1. Negative result implies that antibodies to HCV have not been detected in the sample. This means the patient has either not been exposed to HCV infection or the sample has been tested during the "window phase" i.e. before the development of detectable levels of antibodies. Hence a Non-Reactive result does not exclude the possibility of exposure or infection with HCV.
- 2. Positive result implies that antibodies to HCV have been detected in the sample.

#### Comments :-

Hepatitis C (HCV) is an RNA virus of Flavivirus group transmitted via blood transfusions, transplantation, injection drug users, accidental needle punctures in healthcare workers, dialysis patients and rarely from mother to infant. 10% of new cases show sexual transmission. As compared to HAV & HBV, chronic infection with HCV occurs in 85% of infected individuals. In high risk populations, the predictive value of Anti HCV for HCV infection is > 99% whereas in low risk populations it is only 25%.



1. False positive results are seen in Autoimmune diseases, Rheumatoid factor, Hypergammaglobulinemia, Paraproteinemia, passive antibody transfer, Anti-idiotypes & Anti superoxide dismutase

2. False negative results are seen in early Acute infection, Immunosuppression & Immuno-incompetence

3. HCV RNA PCR recommended in all Reactive results to differentiate between past and present infection

\*\*\* End Of Report \*\*\*

Laboratory is NABL Accredited





DR. RUTURAJ MANIKLAL KOLHAPURE MD, MICROBIOLOGIST



Registered Office:- # Plot No. 564, 1st floor, Buddhanagar, Near Sai Baba Temple Peerzadiguda Boduppal Hyderabad, Telangana. ICMR Reg.No. SAPALAPVLHT (Covid -19) Ph:- 040-40125441, Email:- info@sagepathlabs.com Website:- www.sagepathlabs.com

REPORT -

	REPOR		
Name	: Mrs. SRAVANTHI	Sample ID	: 24854403
Age/Gender	: 42 Years/Female	Reg. No	: 0312310020033
Referred by	: Dr. TEJASHWI	SPP Code	: SPL-CV-172
Referring Customer	: V CARE MEDICAL DIAGNOSTICS	Collected On	: 02-Oct-2023 12:31 PM
Primary Sample	: Whole Blood	Received On	: 02-Oct-2023 12:56 PM
Sample Tested In	: Serum	Reported On	: 02-Oct-2023 07:27 PM
Client Address	: Kimtee colony ,Gokul Nagar,Tarnaka	Report Status	: Final Report

OSE INFOSYSTEMS PVT. LTD.

IMMUNOLOGY & SEROLOGY				
SURGICAL PROFILE-II				
Test Name	Results	Units	Ref. Range	Method
HIV (1& 2) Antibody	0.25	S/Co	< 1.00 : Negative > 1.00 : Positive	ELISA

Correlate Clinically.

Laboratory is NABL Accredited

\*\*\* End Of Report \*\*\*

Excellence In Health Care









DR. RUTURAJ MANIKLAL KOLHAPURE MD, MICROBIOLOGIST